$41.40+0.85 (+2.10%)
At close: Oct 2, 2026, 4:00 PM ET
UroGen Pharma Ltd · Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
13F fund flowQuarter ended Jun 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (39 new · 61 increased · 55 reduced · 21 closed · 35 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 94 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
87.6%
211 filers, Jun 30, 2026
# 13F FUNDS
211
13F VALUE
$1.6B
42.8M shares
Basis: shares reported by 211 13F filers for Jun 30, 2026, over shares outstanding implied from the current quote, measured 94 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price | SEC filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 871 | $42.92 | ↗ |
| Sep 8, 2026 | Smith Jason Drew | General Counsel | Disposed · Open-market sale | 1,519 | $42.54 | ↗ |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | Acquired · Option exercise | 1,667 | — | ↗ |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Option exercise | 1,667Restricted Stock Units | — | ↗ |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | Acquired · Option exercise | 3,334 | — | ↗ |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | Disposed · Option exercise | 3,334Restricted Stock Units | — | ↗ |
| Aug 26, 2026 | Robinson James A. Jr. | director | Acquired · Option exercise | 2,000 | — | ↗ |
| Aug 26, 2026 | Robinson James A. Jr. | director | Disposed · Option exercise | 2,000Restricted Stock Unit | — | ↗ |
| Aug 20, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 60,677 | $47.05 | ↗ |
| Jul 9, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $40.00 | ↗ |
| Jun 22, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $35.01 | ↗ |
| Jun 22, 2026 | Wildman Daniel George | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | Wildman Daniel George | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
| Jun 22, 2026 | Robinson James A. Jr. | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | Robinson James A. Jr. | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
| Jun 22, 2026 | Holden Stuart | director | Acquired · Grant / award | 20,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | BUTITTA CYNTHIA M | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | BUTITTA CYNTHIA M | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
| Jun 22, 2026 | WEN LEANA | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | WEN LEANA | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
!
Lag warningThese holdings were reported for Jun 30, 2026 and are 94 days old, so this is a rear-view mirror, not real-time positioning. Funds have 45 days after each quarter-end to file, which is why the newest complete quarter always runs 45 to 135 days behind.
✓
Price dashes explainedRows with a price of “—” are option exercises / RSU vests or filings reported without a usable per-share price, not $0 trades.
Not investment advice.